This study investigates LY4170156 in participants with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability of the investigational medication.
The study focuses on understanding how effective LY4170156 is for treating these tumors. It evaluates the medication's overall impact on participants' health.
- Who can participate: Adults with specific advanced solid tumors such as ovarian, endometrial, cervical, non-small cell lung, triple negative breast, pancreatic, or colorectal cancer may participate. Key eligibility includes not having uncontrolled CNS metastases or significant cardiovascular disease.
- Study details: Participants will receive the investigational medication. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.
- Study timelines: The study will last up to approximately 4 years.
How understandable was the trial content above?
Hard to understand
Easy to understand